Ethicon

Legal-Bay LLC, tells us that a Federal Jury in West Virginia has awarded a husband and wife $3.27 million in damages against Ethicon, Johnson & Johnson’s mesh product division in what is another loss for transvaginal mesh manufacturers

Ethicon is introducing three new endocutter and energy products at the 19th World Congress of International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO 2014).

Ethicon Endo-Surgery says its newly launched device offers surgeons improved thermal management coupled with greater precision and speed when performing resection during open procedures.

Ethicon Endo-Surgery has launched its HARMONIC ACE®+7 Shears with Advanced Hemostasis, the first purely ultrasonic device with a 7 mm sealing indication. It claims the system outperforms its rival LigaSure™device when it comes to burst pressure.

A Reuters article tells us that Johnson & Johnson has suspended the sale of its power morcellators until the risk of spreading cancerous cells is better understood. This in response to earlier FDA guidance on the subject.

Newly cleared Harmonic Focus® + Shears with so-called Adaptive Tissue Technology promise accurate resection with consequent enhanced speed and surgical precision.

Ethicon Endo-Surgery, Inc. and Megadyne®, Inc have both issued press releases, confirming that they have entered into a collaboration agreement. The deal will see customers offered a contracting solution that incorporates the two companies’ combined product offerings, increasing choice and access to a broad energy portfolio.

Covidien has won a patent infringement suit against Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, relating to Ethicon’s Harmonic® line of ultrasonic surgical products.

Ethicon Endo-Surgery, Inc. has announced the 510(k) clearance from the U.S. FDA for its ENSEAL® G2 Cordless Tissue Sealer Device. Already previously approved in a variety of iterations, the new cordless design is clearly pitched at procedures where speed and range of motion may be critical.

J&J should pay a South Dakota nurse $3.35 million according to the jury in the much-reported vaginal mesh trial. They found that the company had failed to provide adequate warning of risks to the plaintiff’s doctor. J&J’s rebuttal to follow.

The Lawsuit Settlement Funding Company, which has been a public advocate for women victims of various vaginal and pelvic mesh implants, reported today that industry insiders close to the Ethicon Prolift mesh trial have advised them that the plaintiff’s case has raised serious concerns as to what J&J knew about the dangers of their mesh products.

Ethicon Endo-Surgery says its ENSEAL® advanced bipolar devices are strong on sealing, yet gentle on tissue. And now with a new Articulating iteration these benefits can be exploited in the most difficult-to-access anatomies.

Ethicon, a division of J&J, has identified an issue in the packaging process for its SurgiFlo haemostatic matrix. It seems certain products, manufactured between September 16 2011 and July 27 2012 are susceptible to a potential breach of the double Tyvek pouch of the packaging.

Ethicon Biosurgery, has announced that the U.S. Food and Drug Administration (FDA) has approved EVARREST™ Fibrin Sealant Patch, a novel product that it says rapidly and reliably aids in stopping problematic bleeding during surgery.

Ethicon endo’s voluntary recall of certain Proximate Circular staplers during the summer has turned in to an FDA Class I recall due to the serious consequences that can befall the patient in whom the stapler has not completely fired.

J&J division Ethicon, Inc., has followed Covidien into the barbed suture market with the launch of its new portfolio of Stratafix™ Knotless Tissue Control Devices. The idea is that barbed sutures offer significantly more points of fixation than traditional sutures, giving surgeons more consistent control over every pass (through the tissue), and combining the strength and security of interrupted closure with the efficiency of continuous closure.